Objective: To confirm that urate-lowering therapy has a protective effect on renal function in patients with coronary heart disease (CHD) and asymptomatic hyperuricemia undergoing percutaneous coronary intervention (PCI). Methods: A total of 98 patients with coronary heart disease and asymptomatic hyperuricemia undergoing elective PCI were randomly grouped into control group (50 patients) and observation group (48 patients). The control group was hydrated with 0.9 % NaCl solution before and after surgery. In addition to hydration, the observation group started oral benzbromarone 50 mg/d 72 h before surgery. The serum creatinine, serum uric acid (UA), serum Cys-C, serum NGAL, urine NGAL and urine NAG before surgery, 12 h after surgery and 72 h after surgery were compared between the two groups, and the incidence of contrast-induced nephropathy was compared. Results: (1)In the control group, the levels of serum Cys-C, serum NGAL, urinary NGAL and urinary NAG at 12 h after surgery were higher than those before surgery, and the levels of serum creatinine, serum Cys-C and serum NGAL at 72 h after surgery were higher than those before surgery, while in the observation group, the levels of serum UA at two time points after surgery were lower than those before surgery; (2)The levels of serum UA, serum Cys-C, serum NGAL, urine NGAL and urine NAG at 12 h after surgery in the control group were higher than those in the observation group, and the levels of serum UA, serum Cys-C and serum NGAL at 72 h after surgery in the control group were higher than those in the observation group; (3) No contrast-induced nephropathy occurred in the two groups. Conclusion: Preoperative urate-lowering therapy can improve renal function in patients with coronary heart disease and asymptomatic hyperuricemia after PCI.
MA Tiantian
,
SUN Shuyan
,
GAO Yuan
. Effect of urate-lowering therapy on renal function in coronary heart disease patients with asymptomatic hyperuricemia undergoing percutaneous coronary intervention[J]. Journal of Baotou Medical College, 2023
, 39(12)
: 50
-54
.
DOI: 10.16833/j.cnki.jbmc.2023.12.010
[1] Morcos SK, Thomsen HS, Webb JAW. Contrast-media-induced nephrotoxicity: a consensus report[J].Eur Radiol, 1999, 9(8): 1602-1613.
[2] Roth G A, Mensah GA, Johnson CO, et al. Global burden of cardiovascular diseases and risk factors, 1990-2019: update from the GBD 2019 study[J].J Am Coll Cardiol, 2020, 76(25): 2982-3021.
[3] 郭金香,江立千,谭雪莉,等. 探究β_2微球蛋白、胱抑素C、单核细胞趋化蛋白-1在高尿酸血症患者肾功能损害早期诊断中的意义[J].右江医学,2021,49(3):215-219.
[4] 王晋举,张季萌,佘莉萍. 冠状动脉造影及介入治疗后造影剂肾病危险因素的Meta分析[J].中国临床护理,2021,13(8):498-504.
[5] Bae EH, Lim SY, Cho KH, et al. GFR and cardiovascular outcomes after acute myocardial infarction: results from the Korea Acute Myocardial Infarction Registry[J].Am J Kidney Dis, 2012, 59(6): 795-802.
[6] 中国医师协会肾脏内科医师分会. 中国肾脏疾病高尿酸血症诊治的实践指南(2017版)[J].中华医学杂志,2017,97(25):1927-1936.
[7] 严旭亮,代灵巧,李红娟. 高尿酸血症的合理用药[J].临床合理用药杂志,2018,11(28):177-179.
[8] 中华医学会内分泌学分会. 高尿酸血症和痛风治疗的中国专家共识[J].中华内分泌代谢杂志,2013,29(11):913-920.
[9] Lai SW, Liao KF, Kuo YH, et al. Comparison of Benzbromarone and Allopurinol on primary prevention of the first gout flare in asymptomatic hyperuricemia[J].J Pers Med, 2022, 12(5): 697.
[10] White WB, Saag KG, Becker MA, et al. Cardiovascular safety of febuxostat or allopurinol in patients with gout[J].N Engl J Med, 2018, 378(13): 1200-1210.
[11] Gowda S, Desai PB, Kulkarni SS, et al. Markers of renal function tests[J].N Am J Med Sci, 2010, 2(4): 170.
[12] 徐丹,盖延红,刘玲玲. 胱抑素C检测在冠状动脉造影后造影剂肾病诊断中的价值[J].中国当代医药,2012,19(20):109-111.
[13] 高金霞,李秀元,叶虹婷,等. 不同时间点血中性粒细胞明胶酶相关脂质运载蛋白水平与急性肾损伤程度的关系[J].安徽医学,2017,38(2):132-135.
[14] 陈辉乐,徐昌隆,徐晓杰,等. 联合检测血清CysC、NGAL早期诊断冠脉造影剂所致急性肾损害[J].中国中西医结合肾病杂志,2018,19(7):601-603.
[15] 张翩,王玲,何奔,等. 生物标志物NGAL、NAG、胱抑素C诊断对比剂急性肾损伤的价值[J].兰州大学学报(医学版),2018,44(1):7-13.
[16] 张洋,邵静波,苏亮,等. 尿NAG与尿NAG/Cr检测对老年冠心病患者PCI后CIN的诊断价值[J].山东医药,2017,57(29):87-89.
[17] 何兆辉,马光,李敏,等. 非布司他联合水化对伴有高尿酸的冠心病患者造影剂肾病的预防作用[J].实用药物与临床,2021,24(11):1009-1012.
[18] 黄钱娥,蔡琴红,黄宇清,等. 降尿酸药物在冠心病合并高尿酸血症介入术患者中的应用[J].中国当代医药,2020,27(23):50-53.
[19] 潘壮,张丽华,牛少辉,等. 非布司他对冠心病合并高尿酸血症患者术后发生造影剂肾病的影响研究[J].中国全科医学,2019,22(29):3565-3569.
[20] Maloberti A, Biolcati M, Ruzzenenti G, et al. The role of uric acid in acute and chronic coronary syndromes[J].J Clin Med, 2021, 10(20): 4750.
